4-aminopyridine has been researched along with Body Weight in 12 studies
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fampridine (4-aminopyridine) is a potassium channel-blocking agent that has been reported to have therapeutic potential for improving walking and mobility in patients with multiple sclerosis (MS)." | 5.14 | Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a Phase I-II, open-label trial. ( Henney, HR; Vollmer, T, 2009) |
| "The primary objective of this study, which followed on from the single-dose pharmacokinetic study, was to assess the steady-state pharmacokinetics of fampridine in patients with MS over 2 weeks of oral administration of open-label fampridine SR 20 mg BID." | 2.74 | Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study. ( Blight, AR; Henney, HR; Vollmer, T, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 7 (58.33) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Samara, E | 1 |
| Winkle, P | 1 |
| Pardo, P | 1 |
| Henney, HR | 3 |
| Way, SL | 1 |
| Brown, E | 1 |
| Lee, A | 1 |
| Blight, AR | 2 |
| Goddeyne, C | 1 |
| Nichols, J | 1 |
| Wu, C | 1 |
| Anderson, T | 1 |
| Vollmer, T | 2 |
| Porto, NP | 1 |
| Jucá, DM | 1 |
| Lahlou, S | 1 |
| Coelho-de-Souza, AN | 1 |
| Duarte, GP | 1 |
| Magalhães, PJ | 1 |
| Bubolz, AH | 1 |
| Li, H | 1 |
| Wu, Q | 1 |
| Liu, Y | 1 |
| Heywood, JL | 1 |
| McEntee, GM | 1 |
| Stickland, NC | 1 |
| Spöhr, F | 1 |
| Busch, CJ | 1 |
| Reich, C | 1 |
| Motsch, J | 1 |
| Gebhard, MM | 1 |
| Kuebler, WM | 1 |
| Bloch, KD | 1 |
| Weimann, J | 1 |
| Guenthner, CJ | 1 |
| McCaughey, SA | 1 |
| Tordoff, MG | 1 |
| Baird, JP | 1 |
| Bénitah, JP | 1 |
| Gomez, AM | 1 |
| Bailly, P | 1 |
| Da Ponte, JP | 1 |
| Berson, G | 1 |
| Delgado, C | 1 |
| Lorente, P | 1 |
| McDaniel, SS | 1 |
| Platoshyn, O | 1 |
| Yu, Y | 1 |
| Sweeney, M | 1 |
| Miriel, VA | 1 |
| Golovina, VA | 1 |
| Krick, S | 1 |
| Lapp, BR | 1 |
| Wang, JY | 1 |
| Yuan, JX | 1 |
| Sharp, NA | 1 |
| Neel, DS | 1 |
| Parsons, RL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Dalfampridine After Optic Neuritis to Improve Visual Function in Multiple Sclerosis[NCT01337986] | Phase 2/Phase 3 | 53 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Phase 2 Study of 4-Aminopyridine for the Treatment of Episodic Ataxia Type 2[NCT01543750] | Phase 2 | 0 participants (Actual) | Interventional | Withdrawn | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Intent to treat analysis of treatment effect in primary endpoint EDTRS 5% Contrast Sensitivity. Change in the number of letters able to read while on Dalfampridine and Placebo relative to their baseline scores. (NCT01337986)
Timeframe: Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)
| Intervention | letters (Mean) |
|---|---|
| Dalfampridine | 3 |
| Placebo | 2.5 |
Dalfampridine will change color vision Total Error Scores from baseline on the Farnsworth Munsell 100 Hue Sort Test. Farnsworth Munsell 100 Hue Test requires placing 100 color palettes in the correct order based upon color hue. Scores are determined by the frequency and severity of any displacement in the correct order. One error equates to one misplaced hue, by one step or position. An error score greater than 500 indicates virtually no color discrimination. An error score of 0 indicates no errors in ordering the hues. A Total Error Score of 0 to 128 could be seen in a normal population. (NCT01337986)
Timeframe: Visit 1 (Week 0 - baseline), Visit 2 (Week 3 - postintervention 1) and Visit 3 (Week 8 - post intervention 2)
| Intervention | FM100 Total Error Score (Mean) |
|---|---|
| Dalfampridine | -13.0 |
| Placebo | -10.6 |
Dalfampridine treatment will result in change in quality of life. The National Eye Institute Visual Function Questionnaire consists of 25 questions characterizing visual function at home and in the community. Score ranges from 100 (best) to 0 (worst). (NCT01337986)
Timeframe: Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)
| Intervention | NEI VFQ percentage (Median) |
|---|---|
| Dalfampridine | 0 |
| Placebo | 0 |
Intent to treat analysis of treatment effect in primary endpoint EDTRS 5% Contrast Sensitivity. Improvement from baseline scores. (NCT01337986)
Timeframe: Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)
| Intervention | 5% Contrast LogMAR Score (Mean) |
|---|---|
| Dalfampridine | 0.06 |
| Placebo | 0.05 |
Difference in Pelli- Robson Score at Visits 2 and 3 Relative to Visit 1 on Dalfampridine vs Placebo. Pelli-Robson is scored based upon the numbers read on the chart converted to LogMAR units. The scale is 0.00 (worst) to 2.35 (best). (NCT01337986)
Timeframe: Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)
| Intervention | units on a scale (Mean) |
|---|---|
| Dalfampridine | 0.07 |
| Placebo | 0.06 |
Per Protocol Analysis to assess difference in number of letters on the EDTRS 5% Contrast Sensitivity (LogMAR) Chart scores at visits 2 and 3 Relative to Visit 1 (NCT01337986)
Timeframe: Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)
| Intervention | letters (Mean) |
|---|---|
| Group B: Dalfampridine | 2 |
| Group B: Placebo | 2 |
| Group A: Placebo | 4 |
| Group A: Dalfampridine | 3 |
Per Protocol Analysis to assess differences in EDTRS 5% Contrast Sensitivity (LogMAR) Scores at visits 2 and 3 Relative to Visit 1 on patients taking Dalfampridine vs Placebo. (NCT01337986)
Timeframe: Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)
| Intervention | LogMAR Score (Mean) |
|---|---|
| Group B: Dalfampridine | -0.04 |
| Group B: Placebo | -0.06 |
| Group A: Placebo | -0.08 |
| Group A: Dalfampridine | -0.06 |
(NCT01337986)
Timeframe: Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)
| Intervention | Percentages of eyes that improved (Number) |
|---|---|
| Dalfampridine | 9.7 |
| Placebo | 11.1 |
| Both | 11.1 |
| None | 68.1 |
Percentage of eyes that improved by one-line (5 letters) on the 5% contrast sensitivity chart (NCT01337986)
Timeframe: Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)
| Intervention | Percent of Eyes (Number) |
|---|---|
| Dalfampridine | 11.1 |
| Placebo | 15.3 |
| Both | 37.5 |
| Neither | 36.1 |
Visual evoked potential 60min P100 latency on dalfampridine vs. placebo. (NCT01337986)
Timeframe: Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)
| Intervention | milliseconds (Mean) |
|---|---|
| Dalfampridine | 121.6 |
| Placebo | 120.2 |
"The Visual Field Index (VFI) is a global index that assigns a number between 1% to 100% based on an aggregate percentage of visual function, with 100% being a perfect age-adjusted visual field.~Probability of falling in the best quartile for visual field (VFI) measures (Q1), relative to the three next quartiles for worse VFIs (Q2-4), while on Dalfampridine vs Placebo. Due to the clustered observations at different times in a cross-over design, the visual field data is not suited to a normal theory model and should not be expressed as a continuous variable. Thus, a categorical model that uses a multinomial distribution for measurement of 4 categories was selected for proper statistical modeling, with results expressed as odds ratios." (NCT01337986)
Timeframe: Visit 1 (Week 0 - baseline), Visit 2 (Week 3 - post intervention 1) and Visit 3 (Week 8 - post intervention 2)
| Intervention | Visual Field Index % of normal vision (Mean) | ||
|---|---|---|---|
| Baseline (Visit 1) | Post Intervention 1 (Visit 2) | Post Intervention 2 (Visit 3) | |
| Dalfampridine Then Placebo | 77.53 | 78.50 | 79.71 |
| Placebo Then Dalfampridine | 85.38 | 86.65 | 86.00 |
3 trials available for 4-aminopyridine and Body Weight
9 other studies available for 4-aminopyridine and Body Weight
| Article | Year |
|---|---|
Repetitive mild traumatic brain injury induces ventriculomegaly and cortical thinning in juvenile rats.
Topics: 4-Aminopyridine; Action Potentials; Animals; Animals, Newborn; Body Weight; Brain Injuries; Cerebral | 2015 |
Effects of K+channels inhibitors on the cholinergic relaxation of the isolated aorta of adult offspring rats exposed to maternal diabetes.
Topics: 4-Aminopyridine; Acetylcholine; Aging; Animals; Aorta; Blood Glucose; Body Weight; Diabetes Mellitus | 2010 |
Enhanced oxidative stress impairs cAMP-mediated dilation by reducing Kv channel function in small coronary arteries of diabetic rats.
Topics: 4-Aminopyridine; Animals; Antioxidants; Blood Glucose; Body Weight; Colforsin; Coronary Vessels; Cyc | 2005 |
In ovo neuromuscular stimulation alters the skeletal muscle phenotype of the chick.
Topics: 4-Aminopyridine; Animals; Body Weight; Chick Embryo; In Vitro Techniques; Movement; Muscle Fibers, S | 2005 |
4-Aminopyridine restores impaired hypoxic pulmonary vasoconstriction in endotoxemic mice.
Topics: 4-Aminopyridine; Algorithms; Angiotensin II; Animals; Body Weight; Dose-Response Relationship, Drug; | 2007 |
Licking for taste solutions by potassium-deprived rats: specificity and mechanisms.
Topics: 4-Aminopyridine; Animals; Behavior, Animal; Body Weight; Dose-Response Relationship, Drug; Drinking | 2008 |
Heterogeneity of the early outward current in ventricular cells isolated from normal and hypertrophied rat hearts.
Topics: 4-Aminopyridine; Animals; Aorta, Abdominal; Body Weight; Cardiomegaly; Cells, Cultured; Electrophysi | 1993 |
Anorexic effect of K+ channel blockade in mesenteric arterial smooth muscle and intestinal epithelial cells.
Topics: 4-Aminopyridine; Animals; Appetite Depressants; Body Weight; Calcium; Cells, Cultured; Electrophysio | 2001 |
Influence of thyroid hormone levels on the electrical and mechanical properties of rabbit papillary muscle.
Topics: 4-Aminopyridine; Action Potentials; Aminopyridines; Animals; Body Weight; Electric Stimulation; Elec | 1985 |